BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria

Disc Medicine (IRON)Disc MedicineClinical readout

Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and physician demand Results of the APOLLO study are expected in Q4 2026 WATERTOWN, Mass., March 26, 2026

Related news

IRONDisc Medicine2026-10-19 11:00 EST

Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

IRONDisc Medicine2026-10-18 21:00 EST

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

KPTIKaryopharm Therapeutics2026-05-14 11:30 EST

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment

SNDXSyndax Pharmaceuticals2026-10-12 20:01 EST

Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis

APVOAptevo Therapeutics2026-05-13 12:05 EST

Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

APVOAptevo Therapeutics2026-05-06 12:05 EST

Aptevo Reports 87% Clinical Benefit and 81% Remission in 31 Evaluable Frontline AML Patients Through Cohort 5, Substantially Outperforming Benchmark; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection

ZNTLZentalis2026-05-05 12:00 EST

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

RCKTRocket Pharmaceuticals2026-08-03 11:00 EST

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

ZNTLZentalis2026-05-21 21:39 EST

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

KPTIKaryopharm Therapeutics2026-07-30 20:05 EST

Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-10-21 00:52 EST

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

IRONDisc Medicine2026-10-19 20:01 EST

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

IRONDisc Medicine2026-10-19 11:00 EST

Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

IRONDisc Medicine2026-10-18 21:00 EST

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

IRONDisc Medicine2026-09-09 23:25 EST

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Stock data

Close
76.00 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States